IID572, A New Potentially Best-In-Class β-Lactamase Inhibitor.

Resistance in Gram-negative bacteria to β-lactam drugs is mediated primarily by the expression of β-lactamases and co-dosing of β-lactams with a β-lactamase inhibitor (BLI) is a clinically proven strategy to address resistance. New β-lactamases that are not impacted by existing BLIs are spreading and creating the need for development of novel broader spectrum BLIs. IID572 is a novel broad spectrum BLI of the diazabicyclooctane (DBO) class that is able to restore the antibacterial activity of piperacillin against piperacillin/tazobactam-resistant clinical isolates. IID572 is differentiated from other DBOs by its broad inhibition of β-lactamases, and the lack of intrinsic antibacterial activity.